<DOC>
	<DOCNO>NCT00374842</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety candidate vaccine compare Fluarixâ„¢ administer intramuscularly subject age 18-59 year</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety 2 Formulations GlaxoSmithKline ( GSK ) Biologicals ' GSK1247446A Low Dose Influenza Vaccine Candidate</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female age 1859 year time first vaccination . Free obvious health problem Use nonregistered product Administration immunemodifying drug . Administration vaccine 30 day enrolment study . Immunosuppressive immunodeficient condition . Hypersensitivity previous dose influenza vaccine Previous vaccination influenza 2006 Acute chronic clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality . History confirm influenza infection within last 12 Months . Acute disease time enrolment/vaccination . History allergy reaction likely exacerbate component vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Influenza vaccine</keyword>
	<keyword>Prophylaxis Influenza vaccine</keyword>
</DOC>